Acta Médica Portuguesa, 2023 Introduction: Genomic assays are useful tools for tailoring adjuvant treatment in early breast cancer. We aimed to analyse the role of an institutional protocol of a genomic assay for chemotherapy de-escalation.
Diogo Martins-Branco +6 more
doaj +1 more source
Antiestrogen therapy in recurrent ovarian cancer resulting in 28 months of stable disease: A case report and review of the literature [PDF]
Archive of Oncology, 2010 Hormonal therapy for adjuvant treatment of ovarian cancer may provide a low toxicity option in some patients with refractory disease. A 53 year-old patient with stage IIIC papillary serous ovarian cancer previously treated with multiple chemotherapy ...
Carter Jori +4 more
doaj +1 more source
Sexual quality of life in hormonotherapy for breast cancer patients
Brazilian Journal of Oncology, 2022 Objectives: To evaluate how hormonal therapy can impact breast cancer patients sexual quality of life and compare two widely used therapeutic agents: anastrozole and tamoxifen. Studies so far have evaluated the side effects of such therapy on
Pedro Paulo Perroni da Silva +7 more
doaj +1 more source
DRUGS PROVIDED TO BREAST CANCER PATIENTS WITHIN THE STATE PROGRAMS OF DRUG SUPPLY
Фармакоэкономика, 2016 The purpose of our research was to analyze the actual practice of medicine in patients with breast cancer in various regions of the Russian Federation in the framework of state programs of drug provision (procurement of essential drugs (EDPP) and of ...
M. V. Avxentyeva +6 more
doaj +1 more source
Cardiovascular Complications of Prostate Cancer Treatment
Frontiers in Pharmacology, 2020 Treatment of prostate cancer (PC) is a rapidly evolving field of pharmacology research. In recent years, numerous novel therapeutics that improve survival and ameliorate disease control have been approved.
Michał Wilk +2 more
doaj +1 more source
Medical treatment of early stage and rare histological variants of epithelial ovarian cancer [PDF]
, 2015 Epithelial ovarian cancer is often considered a single pathological entity, but increasing evidence suggests that it is rather a group of different neoplasms, each with unique pathological characteristics, molecular features, and clinical behaviours ...
Biglia, Nicoletta +6 more
core +3 more sources
Adherence to prescribing restrictions for HER2-positive metastatic breast cancer in Australia: A national population-based observational study (2001-2016) [PDF]
, 2018 Background: Targeted cancer therapy is often complex, involving multiple agents and chemotherapeutic partners. In Australia, prescribing restrictions are put in place to reflect existing evidence of cost-effectiveness of these medicines.
Daniels, Benjamin +6 more
core +2 more sources
Case Reports in Oncology, 2022 Cyclin4/6-dependent kinase inhibitors (CDKIs) plus hormonotherapy currently represent the standard golden treatment for patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor-2-negative (her-2−) advanced breast carcinoma ...
Vittorio Gebbia
doaj +1 more source
Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer. Efficacy in combination with hormonal therapy [PDF]
, 2012 Background: Data on efficacy of bevacizumab (B) beyond first-line taxane -including regimen (BT) as first-line treatment are lacking. Although preclinical results that anti-angiogenic agents combined with hormonal therapy (HT) could be active, no ...
Cognetti F. +10 more
core +3 more sources
The role of estrogen receptors isoforms in breast cancer [PDF]
Archive of Oncology, 2006 Background: Estrogen and progesterone receptor (ER/PR) status is an accepted predictive marker in breast cancer. It is well known that breast tumors, which are ER(+) are more likely to respond to endocrine therapy. However, certain percentage of ER(+)/PR(
Mandušić Vesna +5 more
doaj +1 more source